The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.
There are plenty of tips on how to lose weight fast without exercise, from sketchy pills to crash diets that do more harm ...
The Biden administration says it will be including weight loss drugs like Ozempic and Wegovy in the next round of drug ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback